Senate Drug Import Bill Would Require Notice Of Manufacturing Changes
Executive Summary
Drug manufacturers would be required to notify FDA of any manufacturing changes that might serve to circumvent reimportation under bipartisan legislation introduced by Sens. Byron Dorgan (D-N.D.) and Edward Kennedy (D-Mass.) April 21
You may also be interested in...
Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight
A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight
Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight
A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight
Rx Import Debate Launches In Senate With Introduction Of Four Bills
The drug importation debate was launched in the Senate the week of Jan. 24 with the introduction of several bills